サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468354

胃がん治療薬の市場レポート：タイプ、投与経路、エンドユーザー、地域別、2024～2032年

Gastric Cancer Drugs Market Report by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
胃がん治療薬の市場レポート：タイプ、投与経路、エンドユーザー、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の胃がん治療薬市場規模は2023年に46億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに125億米ドルに達し、2024～2032年の間に11.26%の成長率（CAGR）を示すと予測しています。慢性と急性の適応症の有病率の上昇、体重関連の健康懸念の増加、健康意識の高まりが、市場を牽引する主要要因のいくつかです。

胃がん治療薬は、胃の粘膜に悪性細胞が形成される胃がんと診断された患者を緩和または治療するために開発された医薬品です。胃がんの一般的な症状としては、原因不明の体重減少、消化不良、腹部膨満感、吐き気、嘔吐、胸やけ、食べ物の飲み込みにくさなどがあります。塩酸ドキソルビシン、スニチニブ、マイトマイシン、フルオロウラシル、イマチニブ、ドセタキセルが一般的に使用されている胃がん治療薬です。これらの薬剤は、がん細胞の一部を死滅させることによって腫瘍を縮小させ、がんの徴候や症状を緩和するのに役立ちます。また、がん細胞が増殖したり、分裂したり、細胞を増やしたりするのを抑える働きもあります。その結果、胃がん治療薬は経口剤や非経口剤で投与され、病院、クリニック、特別治療センターで使用されています。

高齢者人口の増加と世界の肥満の有病率の上昇が、主に市場成長の原動力となっています。これに伴い、不健康な食習慣や座りっぱなしの生活スタイルによる体重関連の健康懸念が増加していることも、市場の成長を後押ししています。さらに、タバコやアルコール飲料の消費増加によるがんの増加や、予防・治療へのニーズの高まりも成長を促す要因となっています。これとは別に、腫瘍の増殖を抑える2つの胃がんバイオマーカーの採用が市場成長に弾みをつけています。さらに、メーカーは胃びらんや吐き気などの副作用を最小限に抑えた製品の開発に注力しており、市場の成長を後押ししています。これとともに、効果的で特異的ながん治療薬法の開拓に焦点を当てた急速な技術進歩が、市場に明るい展望をもたらしています。さらに、大手製薬企業や主要参入企業は、より安全で、より効果的で、経済的に実行可能で、より投与しやすい胃がん治療薬を開発するために、研究開発（R&D）活動に多額の投資を行っています。これに加えて、メーカーが製造する医薬品の品質を確保するために、医薬品の製造、加工、包装を促進するさまざまな政府の取り組みが実施されていることも、市場の成長にプラスの影響を与えています。医療支出の増加、胃がんの症状や利用可能な治療オプションに関する消費者の意識の高まりなど、その他の要因も市場成長を促進すると予想されます。

本レポートで扱う主要質問

  • 世界の胃がん治療薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 胃がん治療薬の世界市場における市場の促進要因、抑制要因、機会は何か？
  • 主要な地域市場は？
  • 最も魅力的な胃がん治療薬市場はどの国か？
  • タイプ別の市場内訳は？
  • 投与経路別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 世界の胃がん治療薬市場の競争構造は？
  • 胃がん治療薬の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 胃がん治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 塩酸ドキソルビシン
  • スニチニブ
  • ドセタキセル
  • マイトマイシン
  • フルオロウラシル
  • イマチニブ
  • トラスツズマブ

第7章 市場内訳：投与経路別

  • 経口
  • 非経口

第8章 市場内訳：エンドユーザー別

  • 病院
  • クリニック
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Arog Pharamaceuticals Inc.
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and company
    • F. Hoffmann-La Roche AG
    • Ono Pharmaceutical Co. Ltd.
    • Sanofi S.A.
    • Taiho Pharmaceutical Co. Ltd.（Otsuka Pharmaceutical Co. Ltd.）
図表

List of Figures

  • Figure 1: Global: Gastric Cancer Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Gastric Cancer Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Gastric Cancer Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Gastric Cancer Drugs Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Gastric Cancer Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Gastric Cancer Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Gastric Cancer Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Gastric Cancer Drugs (Sunitinib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Gastric Cancer Drugs (Sunitinib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Gastric Cancer Drugs (Docetaxel) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Gastric Cancer Drugs (Docetaxel) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Gastric Cancer Drugs (Mitomycin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Gastric Cancer Drugs (Mitomycin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Gastric Cancer Drugs (Fluorouracil) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Gastric Cancer Drugs (Fluorouracil) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Gastric Cancer Drugs (Imatinib) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Gastric Cancer Drugs (Imatinib) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Gastric Cancer Drugs (Trastuzumab) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Gastric Cancer Drugs (Trastuzumab) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Gastric Cancer Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Gastric Cancer Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Gastric Cancer Drugs (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Gastric Cancer Drugs (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Gastric Cancer Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Gastric Cancer Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Gastric Cancer Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Gastric Cancer Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Gastric Cancer Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Gastric Cancer Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Gastric Cancer Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Gastric Cancer Drugs Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Gastric Cancer Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 82: Global: Gastric Cancer Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Gastric Cancer Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Gastric Cancer Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Gastric Cancer Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Gastric Cancer Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Gastric Cancer Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Gastric Cancer Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Gastric Cancer Drugs Market: Competitive Structure
  • Table 7: Global: Gastric Cancer Drugs Market: Key Players
目次
Product Code: SR112024A6648

The global gastric cancer drugs market size reached US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.26% during 2024-2032. The rising prevalence of chronic and acute indications, growing incidences of weight-related health concerns, and increasing health consciousness represent some of the key factors driving the market.

Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.

The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth. Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer. Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global gastric cancer drugs market, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, route of administration, and end user.

Type Insights

Doxorubicin Hydrochloride

Sunitinib

Docetaxel

Mitomycin

Fluorouracil

Imatinib

Trastuzumab

The report has provided a detailed breakup and analysis of the gastric cancer drugs market based on the type. This includes doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. According to the report, trastuzumab represented the largest segment.

Route of Administration Insights

Oral

Parenteral

A detailed breakup and analysis of the gastric cancer drugs market based on the route of administration has also been provided in the report. This includes oral and parenteral. According to the report, parenteral accounted for the largest market share.

End User Insights

Hospitals

Clinics

Others

The report has also provided a detailed breakup and analysis of the gastric cancer drugs market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.

Regional Insights

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, Asia Pacific was the largest market for gastric cancer drugs. Some of the factors driving the Asia Pacific gastric cancer drugs market included its high healthcare expenditure, technological advancements, and rising geriatric population.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global gastric cancer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Arog Pharamaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global gastric cancer drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global gastric cancer drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive gastric cancer drugs market?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on end user?
  • What is the competitive structure of the global gastric cancer drugs market?
  • Who are the key players/companies in the global gastric cancer drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Gastric Cancer Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Doxorubicin Hydrochloride
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Sunitinib
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Docetaxel
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mitomycin
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Fluorouracil
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Imatinib
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Trastuzumab
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parenteral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Arog Pharamaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Daiichi Sankyo Company Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Eli Lilly and company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ono Pharmaceutical Co. Ltd.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Sanofi S.A.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report